Xianping Lu

2.7k citations

44 papers · 1.7k indexed · 1 hit paper · h-index 21

Impact in

Oncology top 5%
- Peptidase Inhibition and Analysis
Molecular Biology top 10%
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
- Peroxisome Proliferator-Activated Receptors
- Epigenetics and DNA Methylation

Papers in ⓘ

Molecular Biology 32
- Histone Deacetylase Inhibitors Research 13
- Protein Degradation and Inhibitors 9
- Peroxisome Proliferator-Activated Receptors 7
- Retinoids in leukemia and cellular processes 6
Oncology 14
- Peptidase Inhibition and Analysis 7

Co-authors: Zhiqiang Ning (16 shared papers)Desi Pan (15 shared papers)Zhibin Li (6 shared papers)Haixiang Cao (5 shared papers)Song Shan (6 shared papers)Mei Dong (3 shared papers)Shan Song (6 shared papers)Magnus Pfahl (6 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (2 papers)PPAR Research (2 papers)International Journal of Cancer (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)Nature Medicine (1 paper)
Partner nations: China United States Hong Kong

In The Last Decade

Xianping Lu

41 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Advances in targeting histone deacetylase for treatment of solid tumors 2024 · 56 citations

Peers

Countries citing papers authored by Xianping Lu

Since Specialization

Citations

This map shows the geographic impact of Xianping Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xianping Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xianping Lu more than expected).

Fields of papers citing papers by Xianping Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xianping Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xianping Lu. The network helps show where Xianping Lu may publish in the future.

Co-authors

The 25 scholars most cited alongside Xianping Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xianping Lu Line = papers co-authored together Xianping Lu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma Annals of Oncology ·Yue Shi, Mei Dong, Xiaoting Hong, Wen Zhang, J. Feng, Jing-Zhong Zhu, Li Yu, Xiao Ke, He Huang, Z. Shen, Yun Fan, W. Li, Xiaohong Zhao, Jianyong Qi, Daobin Zhou, Zhengwen Ning, Xianping Lu	2015	263
2	Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity Cancer Chemotherapy and Pharmacology ·Zhiqiang Ning, Zhibin Li, Michael Newman, Song Shan, Xinhao Wang, Desi Pan, Jin Zhang, Mei Dong, Xin Du, Xianping Lu	2011	221
3	Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China Intractable & Rare Diseases Research ·Xianping Lu, Zhiqiang Ning, Zhibin Li, Haixiang Cao, Xinhao Wang	2016	127
4	Naringenin and hesperetin, two flavonoids derived from Citrus aurantium up‐regulate transcription of adiponectin Phytotherapy Research ·Li Liu, Shan Song, Kun Zhang, Zhiqiang Ning, Xianping Lu, Yiyu Cheng	2008	103
5	Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas Cancer Chemotherapy and Pharmacology ·Mei Dong, Zhiqiang Ning, Pu-yuan Xing, Jia-Lian Xu, Haixiang Cao, Guifang Dou, Zhiyun Meng, Yuankai Shi, Xianping Lu, Feng-yi Feng	2012	90
6	Novel retinoid-related molecules as apoptosis inducers and effectve inhibitors of human lung cancer cells in vivo Nature Medicine ·Xianping Lu, Andrea Fanjul, Nathalie Picard, Michaela Pfahl, Deepa Rungta, Karen Nared Hood, Bruce Carter, Javier Piedrafita, Shiping Tang, Eric Fabbrizio, Magnus Pfahl	1997	71
7	The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats British Journal of Pharmacology ·Pingping Li, Shan Song, Yue-teng Chen, Zhiqiang Ning, Sujuan Sun, Quan Liu, Xianping Lu, Mingzhi Xie, Zhufang Shen	2006	58
8	Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells Biomedicine & Pharmacotherapy ·You Zhou, Desi Pan, Song Shan, Jing-Zhong Zhu, Kun Zhang, Xupeng Yue, Liping Nie, Jun Wan, Xianping Lu, Wei Zhang, Zhiqiang Ning	2014	57
9	Nuclear Retinoid Receptors and Their Mechanism of Action Vitamins and hormones ·Magnus Pfahl, Rainer Apfel, Igor Bendik, Andrea Fanjul, Gerhart Graupner, Mi‐Ock Lee, Nathalie La-Vista, Xianping Lu, Javier Piedrafita, María A. Ortiz, Gilles Salbert, Xiao-kun Zhang	1994	57
10	Advances in targeting histone deacetylase for treatment of solid tumors Journal of Hematology & Oncology ·Mu-Qi Shi, Ying Xu, Xin Fu, Desi Pan, Xianping Lu, Yi Xiao, Yi‐Zhou Jiang Hit paper breakdown →	2024	56
11	Progastrin_1–80stimulates growth of intestinal epithelial cells in vitro via high-affinity binding sites American Journal of Physiology-Gastrointestinal and Liver Physiology ·Pomila Singh, Xianping Lu, Stephanie A. Cobb, Brian T. Miller, Nadya I. Tarasova, Andrea Varró, Azar Owlia	2003	52
12	Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment Frontiers in Pharmacology ·Yi-Chen Sun, Jing Han Hong, Zhiqiang Ning, Desi Pan, Xin Fu, Xianping Lu, Jing Tan	2022	47
13	In VitroandIn VivoCharacterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist PPAR Research ·Bing He, Zhengwen Ning, Zeqian Li, Shan Song, Desi Pan, Ben C.B. Ko, Pingping Li, Zhufang Shen, Guifang Dou, B. L. Zhang, Xianping Lu, Yue Gao	2012	41
14	Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment MedChemComm ·Desi Pan, Qian‐Jiao Yang, Xin Fu, Song Shan, Jing-Zhong Zhu, Kun Zhang, Zhibin Li, Zhiqiang Ning, Xianping Lu	2014	41
15	Down-regulation of prostate specific antigen in LNCaP cells by flavonoids from the pollen of Brassica napus L. Phytomedicine ·Haiyan Han, Sharui Shan, X. Zhang, Naixuan Wang, Xianping Lu, Xin‐Sheng Yao	2006	38
16	Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors PubMed ·Aihua Xie, Chenzhong Liao, Zhibin Li, Zhiqiang Ning, Weiming Hu, Xianping Lu, Leming Shi, Jiaju Zhou	2004	37
17	CS2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency Cancer Science ·You Zhou, Song Shan, Zhibin Li, Lijun Xin, Desi Pan, Qian‐Jiao Yang, Ying‐Ping Liu, Xupeng Yue, Xiaorong Liu, Ji‐Zhou Gao, Jin‐Wen Zhang, Zhiqiang Ning, Xianping Lu	2016	37
18	DNA bending by retinoid X receptor-containing retinoid and thyroid hormone receptor complexes. Molecular and Cellular Biology ·Xianping Lu, Norman L. Eberhardt, Magnus Pfahl	1993	36
19	A selective retinoid with high activity against an androgen-resistant prostate cancer cell type International Journal of Cancer ·Xianping Lu, Andrea Fanjul, Nathalie Picard, Braham Shroot, Magnus Pfahl	1999	34
20	Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ PPAR Research ·Desi Pan, Wei Wang, Nansong Liu, Qian‐Jiao Yang, Kun Zhang, Jing-Zhong Zhu, Shan Song, Zhibin Li, Zhiqiang Ning, Laiqiang Huang, Xianping Lu	2017	32

About Xianping Lu

Xianping Lu is a scholar working on Molecular Biology, Oncology, Physiology, Genetics and Cancer Research, having authored 44 papers that have together received 1.7k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (13 papers), Protein Degradation and Inhibitors (9 papers), Peroxisome Proliferator-Activated Receptors (7 papers), Peptidase Inhibition and Analysis (7 papers), Retinoids in leukemia and cellular processes (6 papers), Estrogen and related hormone effects (4 papers), Adipose Tissue and Metabolism (4 papers) and Computational Drug Discovery Methods (3 papers). The work is most often cited by research in Oncology (505 citations), Molecular Biology (1.2k citations), Pathology and Forensic Medicine (267 citations), Biochemistry (85 citations) and Hematology (120 citations). Xianping Lu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Zhiqiang Ning, Desi Pan, Zhibin Li, Haixiang Cao, Song Shan, Mei Dong, Shan Song, Magnus Pfahl, Jing-Zhong Zhu and Xinhao Wang. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, PPAR Research, International Journal of Cancer, Cancer Chemotherapy and Pharmacology and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact